Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113445 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
A Phase 3 study of NonSegmental Vitiligo, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
- 20
- Study locations
NCT06113445 is a Phase 3 study of NonSegmental Vitiligo that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 467 participants, above the 277-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06113445, a Phase 3 study of NonSegmental Vitiligo, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Povorcitinib
Study Locations (20)
Florida
- Renaissance Research - Cape Coral
- Encore Medical Research, Llc - Hollywood
- Savin Medical Group, Rc - Miami
- Skin Research of South Florida, Llc - Miami
- San Marcus Research Clinic Inc. - Miami Lakes
- Olympian Clinical Research - Tampa
- Forcare Clinical Research - Tampa
California
- University of California Irvine - Irvine
- Clinical Science Institute Clinical Research Specialists Inc - Santa Monica
- Cura Clinical Research - Sherman Oaks
- Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale Center - Sunnyvale
Georgia
- Cleaver Medical Group - Cumming
- Dermatology and Surgery Specialists of North Atlanta - Marietta
- Pivotal Research Solutions - Stonecrest
Massachusetts
- Allcutis Research, Llc - Beverly
- Metro Boston Clinical Partners - Brighton
Michigan
- Great Lakes Research Group Inc - Bay City
- Wayne State University Physician Group Dermatology - Dearborn
Alabama
- Cahaba Dermatology - Hoover
Indiana
- Options Research Group, Llc - Kokomo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2027-02-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06113445
The ClinicalTrials.gov registry entry for NCT06113445 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 277-participant average among 3 other NonSegmental Vitiligo trials with a reported enrollment target (69% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NonSegmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06113445 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06113445 about?
NCT06113445 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)". This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
What is the current status of trial NCT06113445?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2023-11-29. Estimated completion is 2027-02-24.
What conditions does trial NCT06113445 study?
This clinical trial studies the following conditions: NonSegmental Vitiligo.
What interventions are being tested in trial NCT06113445?
The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06113445?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06113445 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NonSegmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.